Oxford University Innovation Q3 2018 Update
Oxford spinouts secure £130m in August alone as OUI heads towards a potentially record breaking year for spinout generation.
Oxford spinouts secure £130m in August alone as OUI heads towards a potentially record breaking year for spinout generation.
Oxford University spinout Caristo Diagnostics utilises standard CT scans to identify potentially heart-stopping plaques.
Subsidiaries of the Oxford University spinout, OxStem Immuno and OxStem Beta, will draw on research from the institution.
Oxford University Innovation unveils support for impact-driven businesses from academic ideas.
The University of Oxford spinout also inks clinical paper in Lancet Psychiatry, appoints CEO and sets up Oxford HQ and London development hub.
Dr. Georg C. Terstappen has been appointed to the role of Chief Scientific Officer (CSO) of spinout OxStem Ltd.
The Oxford University spinout will use the investment to further develop its exosome technology, capable of delivering drugs to previously inaccessible parts of the body.
Celleron Therapeutics, spun out of the University in 2005, has commenced a Phase Ib/II clinical trial investigating drug combination therapy for colorectal cancer.
Oxford University spinout external investment nears £1.9bn since 2011 - £506m of which was in the past twelve months.
Opsydia, an Oxford University spinout founded last year to create a new level of diamond and gemstone security, officially launches with De Beers deal.